{
  "authors": [
    {
      "author": "Laura Niccoli"
    },
    {
      "author": "Emanuele Cassar√†"
    },
    {
      "author": "Olga Kaloudi"
    },
    {
      "author": "Carlotta Nannini"
    },
    {
      "author": "Micaela Romagnoli"
    },
    {
      "author": "Fabrizio Cantini"
    }
  ],
  "doi": "10.1186/s12891-015-0602-6",
  "publication_date": "2015-06-15",
  "id": "EN115265",
  "url": "https://pubmed.ncbi.nlm.nih.gov/26071911",
  "source": "BMC musculoskeletal disorders",
  "source_url": "",
  "licence": "CC BY",
  "language": "en",
  "type": "pubmed",
  "description": "",
  "text": "We treated with anti-interleukin 1 beta targeted antibody canakinumab a 67 year old man with asbestosis and long lasting systemic autoimmune features. A dramatic improvement in clinical manifestations was observed at 1 week after the first injection, with complete clinical remission at 4 months."
}